Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
|
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [11] Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer
    Kunitoh, H
    Watanabe, K
    Nagatomo, A
    Okamoto, H
    Kimbara, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (01): : 103 - 109
  • [12] Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer
    Lochrin, C
    Goss, G
    Stewart, DJ
    Cross, P
    Agboola, O
    Dahrouge, S
    Tomiak, E
    Evans, WK
    LUNG CANCER, 1999, 23 (01) : 19 - 30
  • [13] Sequencing chemotherapy, radiotherapy and surgery in combined modality treatment of stage III nonsmall cell lung cancer
    Maas, Klaartie W.
    El Sharouni, Sherif Y.
    Smit, Egbert F.
    Schramel, Franz M. N. H.
    CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (04) : 297 - 304
  • [14] Preoperative concurrent chemoradiotherapy for unresectable stage III nonsmall cell lung cancer
    Milstein, D
    Kuten, A
    Saute, M
    Best, LA
    Daoud, K
    ZenAlDeen, I
    Dale, J
    Robinson, E
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (05): : 1125 - 1132
  • [15] Concurrent cisplatin, etoposide, and radiotherapy for unresectable Stage III nonsmall cell lung cancer: A Phase II study
    Reboul, F
    Brewer, Y
    Vincent, P
    Chauvet, B
    Faure, CF
    Taulelle, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (02): : 343 - 350
  • [16] Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery
    Caglar, Hale B.
    Baldini, Elizabeth H.
    Othus, Megan
    Rabin, Michael S.
    Bueno, Raphael
    Sugarbaker, David J.
    Mentzer, Steven J.
    Janne, Pasi A.
    Johnson, Bruce E.
    Allen, Aaron M.
    CANCER, 2009, 115 (18) : 4156 - 4166
  • [17] Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with hyperfractionated radiotherapy with/without chemotherapy: A multivariate analysis of 682 RTOG patients
    WernerWasik, M
    Scott, C
    Graham, ML
    Smith, C
    Byhardt, RW
    Roach, M
    Andras, EJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 314 - 314
  • [18] RANDOMIZED TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH OR WITHOUT CONCURRENT CHEMOTHERAPY FOR STAGE-III NON-SMALL-CELL LUNG-CANCER
    JEREMIC, B
    SHIBAMOTO, Y
    ACIMOVIC, L
    DJURIC, L
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) : 452 - 458
  • [19] Phase II study of hyperfractionated radiotherapy and concurrent weekly alternating chemotherapy in limited-stage small cell lung cancer
    Ali, MA
    Kraut, MJ
    Valdivieso, M
    Herskovic, AM
    Du, W
    Kalemkerian, GP
    LUNG CANCER, 1998, 22 (01) : 39 - 44
  • [20] Results Of Proton Beams Radiotherapy Without Concurrent Chemotherapy For Patients With Unresectable Stage III Non-small Cell Lung Cancer
    Oshiro, Y.
    Okumura, T.
    Mizumoto, M.
    Hashimoto, T.
    Fukumitsu, N.
    Ohkawa, A.
    Kanemoto, A.
    Hashii, H.
    Tsuboi, K.
    Sakurai, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S576 - S577